BEACON Pharmaceuticals Limited

Registered Office: 153-154 Tejgaon I/A, Dhaka-1208

Financial Statements 3rd quarter 2011

We forward herewith the un-audited Financial Statements of the Company for the 3rd quarter ended March 31, 2011 as per Notification No, SEC/CMRRCD/2008-183/Admin/03-34 dated 27th September 2009 of the Securities and Exchange Commission. Copies of the statements have also been dispatched to Securities and Exchange Commission, Dhaka Stock Exchange Ltd. and Chittagong Stock Exchange Ltd.

BALANCE SHEET AS AT 31ST MARCH 2011

ASSETS	31.03.11	30.06.10
Non-Current Assets	31103111	30100110
Property, Plant & Equipment	2,590,977,479	2,529,426,272
Deffered IPO Expenses	20,121,329	-,,
Current Assets	1.600.494.109	1,120,732,011
Inventories	858,726,101	667,168,268
Accounts Receivables	99.659.048	68,041,157
Spares & Supplies	93,272,792	-
Advance, Deposits & Pre-payments	492,471,041	358,910,015
Cash & Bank Balances	56,365,127	26,612,571
Investment in Shares	2,000,000	2,000,000
TOTAL ASSETS Tk.	4,213,592,917	3,652,158,283
SHAREHOLDERS' EQUITY & LIABILITIES		.,,
Shareholders' Equity	2,674,537,918	2,286,852,753
Issued Capital	2,200,000,000	1,900,000,000
Reserve and Surplus	378,430,447	386,631,629
Retained Earnings	96,107,471	221,124
Non-Current Liabilities	986,137,211	940,488,185
Long Term Borrowings - Net off Current Maturity	980,518,333	938,784,335
Liability for EWF and WPPF	5,618,878	1,703,850
Current Liabilities	552,917,788	424,817,345
Short Term Borrowings	370,609,155	262,854,378
Long Term Borrowings -Current Maturity	134,601,122	134,601,122
Share Application Money (Refundable)	7,679,566	-
Accounts Payables	19,395,690	17,800,174
Tax Payable	11,659,750	254,225
Accrued Expenses	8,972,505	9,307,446
TOTAL SHAREHOLDERS' EQUITY & LIABILITIES Tk.	4,213,592,917	3,652,158,283
Net Asset Value (NAV) per share	12.16	12.04

Income Statement

For the 3rd Quarter ended 31st March 2011

Particulars	Jul'10-Mar'11 9 months	Jul'09-Mar'10 9 months	Jan-Mar'11 3rd Qtr	Jan-Mar'10 3rd Qtr
Turnover	506,487,408	391,744,005	176,616,638	132,265,317
Less: Cost of Goods Sold	223,492,743	176,131,025	79,417,830	61,014,351
Gross Profit	282,994,665	215,612,980	97,198,808	71,250,966
Less: Administrative Expenses	18,778,371	17,316,822	7,027,101	7,065,189
Less : Selling, Marketing & Distribution Expenses	85,285,331	63,562,063	36,308,922	21,263,355
	104,063,702	80,878,885	43,336,023	28,328,543
Operating Income	178,930,963	134,734,095	53,862,785	42,922,422
Less: Financial Expenses	124,575,329	126,497,714	39,760,080	31,539,309
Net Profit after Financial Expenses	54,355,634	8,236,381	14,102,705	11,383,113
Income from other Sources	52,463,680	4,885,468	252,908	804,780
Net Profit before IPO Expenses	106,819,314	13,121,849	14,355,613	12,187,893
Deffered IPO Expenses	3,550,824	-	1,183,608	-
Net Profit before contribution to WPPF	103,268,490	13,121,849	13,172,005	12,187,893
Less: Contribution to WPPF	4,917,547	-	627,238	-
Net Profit before Taxation	98,350,943	13,121,849	12,544,767	12,187,893
Income Tax	10,665,778	-	2,986,899	-
Net Profit after Taxation Tk.	87,685,165	13,121,849	9,557,868	12,187,893
Earning Per Share (EPS)	0.40	0.07	0.04	0.06
Nos. of Shares Issued	220,000,000	190,000,000	220,000,000	190,000,000

Cash Flow Statement

For the 3rd Quarter ended 31st March 2011

Particulars	Jul'10-Mar'11 9 months	Jul'09-Mar'10 9 months
Cash Flows from Operating Activities :		
Collection against Sales	474,869,517	382,287,341
Payment to Creditors and Employees	(356,257,499)	(223,701,699)
Other Operating Expenses	(133,048,132)	(109,615,094)
Interest paid	(30,424,265)	(22,164,220)
Net Cash Generated from Operating Activities	(44,860,379)	26,806,328
Cash Flows from Investing Activities:		
Acquisition of Property, Plant & Equipment	(183,746,228)	(95,452,235)
Disposal of Property, Plant & Equipment	-	-
Investment in Shares	-	(2,000,000)
Interest and Other Received	52,463,680	4,885,468
Payment to others	(133,561,026)	(289,910,716)
Net Cash Generated from Investing Activities	s (264,843,574)	(382,477,483)
Cash Flows from Financing Activities :		
Capital Received	300,000,000	1,300,000,000
IPO Expenses (Current & Deffered)	(23,672,153)	-
Excess Share Application Money Refunded	7,790,951	-
Long Term Loan Received	-	-
Long Term Loan Refund	(52,417,066)	(478,277,000)
Short Term Loan Received	368,337,805	81,223,331
Short Term Loan Refund	(260,583,028)	(521,528,543)
Net Cash Generated from Financing Activities	339,456,509	381,417,788
Net Cash Increase / (Decrease)	29,752,556	25,746,633
Cash and Cash Equivalents - Opening	26,612,571	5,772,633
	Γk. 56,365,127	31,519,266
Operating Cash Flow per share	(0.20)	0.14
Nos. of Shares Issued	220,000,000	190,000,000

STATEMENT OF CHANGES IN EQUITY

For the 3rd Quarter ended 31st March 2011					
Particulars	Share Capital	Revaluation Reserve	Tax holiday Reserve	Retained Earnings	Total Equity
At the beginning of the period	1,900,000,000	384,220,144	2,411,485	221,124 2	2,286,852,753
Net profit/(Loss) transferred from the Profit & Loss Account	-	-	-	87,685,165	87,685,165
Revaluation Reserve adjustment	-	(13,292,796)	-	13,292,796	-
Transferred to Tax holiday Reserve	-	-	5,091,614	(5,091,614)	-
Capital Issued during the period	300,000,000	-	-	-	300,000,000
At the end of Tk. the period	2,200,000,000	370,927,348	7,503,099	96,107,471	2,674,537,918

STATEMENT OF CHANGES IN EQUITY

For the 3rd Quarter ended 31st March 2010					
Particulars	Share Capital	Revaluation Reserve	Tax holiday Reserve	Retained Earnings	Total Equity
At the beginning	600,000,000	401,943,872	-	(32,029,546)	969,914,326
of the year					
Net profit/(Loss) trans		-	-	13,121,849	13,121,849
from the Profit & Loss Account					
Revaluation Reserve	-	(13,292,796)	-	13,292,796	-
Capital Issued	1,300,000,000	-	-	-	1,300,000,000
during the period					
At the end of	Tk. 1,900,000,000	388,651,076	-	(5,614,901)	2,283,036,175
the period					





Managing Director

CO Ε <u>A</u> Pharmaceuticals Limited

a company with global vision

The details of the published 3rd quartely financial statements are available in the website of the Company. www.beacon-pharma.com